Oncolytics Biotech (TSE:ONC) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Oncolytics Biotech is set to discuss its third-quarter financial results and recent operational achievements in an upcoming conference call. The company, known for its promising cancer immunotherapy, pelareorep, is advancing towards key registrational studies after receiving fast-track designations from the FDA.
For further insights into TSE:ONC stock, check out TipRanks’ Stock Analysis page.